Fig. 2: Subgroup analyses of overall survival (OS) in MDACC-primary cohort first-line patients (n = 675) stratified by chemotherapy administration in the 2nd line. | Nature Communications

Fig. 2: Subgroup analyses of overall survival (OS) in MDACC-primary cohort first-line patients (n = 675) stratified by chemotherapy administration in the 2nd line.

From: Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer

Fig. 2

a Analysis schema. b Kaplan–meier plot of OS of all first-line patients stratified by sequential vs combination chemotherapy; c OS in patients with PD-L1 intermediate (1%–49%) or low (0 or <1%); and d OS in patients with PD-L1 high (≥50%). P values were calculated using log-rank analysis. Source data are provided as a Source Data file. ICI-mono only: immune checkpoint inhibitor (ICI) monotherapy; ICI-chemo: concurrent ICI and chemotherapy; ICI-mono then chemo: sequential ICI monotherapy followed by chemotherapy.

Back to article page